Milestone Pharmaceuticals Inc — Liquidità Trimestrale (NASDAQ:MIST) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 75.5 M61.88 M47.42 M87.75 M113.56 M Totale passività 62.35 M68.01 M65.16 M67.25 M71.79 M Patrimonio netto totale 13.15 M-6.12 M-17.75 M20.5 M41.77 M Totale passività e patrimonio netto 75.5 M61.88 M47.42 M87.75 M113.56 M Debito totale 54.8 M55.05 M55.88 M56.73 M58.38 M Indebitamento netto -14.9 M-955 K12.48 M-25.88 M-47.62 M

Notizie

Milestone Pharmaceuticals pianifica studio di registro PSVT nel mondo reale

Raymond James avvia la copertura di Milestone Pharmaceuticals con Strong Buy

Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

Transcript della relazione sugli utili: Milestone Pharmaceuticals raggiunge le previsioni EPS, titolo in calo

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Stock: Downgrading To Sell As CARDAMYST Faces A Tough Reality (NASDAQ:MIST)

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Il trattamento CARDAMYST di Milestone per la TPSV ora disponibile nelle farmacie USA

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)

I regolatori europei accettano la domanda per lo spray nasale etripamil per PSVT